A randomized controlled trial of prednisone in Alzheimer's disease

Neurology

Volumn 54, Issue 3, 2000, Pages 588-593

  Aisen, Paul S ^a   Davis, K L ^b   Berg, J D ^c   Schafer, K ^c   Campbell, K ^c   Thomas, R G ^c   Weiner, M F ^e   Farlow, M R ^f   Sano, M ^g   Grundman, M ^d   Thal, L J ^d  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f INDIANA UNIVERSITY   (United States)

^g Vagelos College of Physicians and Surgeons   (United States)

Author keywords

AD; Anti inflammatory therapy; Glucocorticoids; Randomized controlled trial

Indexed keywords

ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PLACEBO; PREDNISONE;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CAPILLARY RESISTANCE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EDEMA; FEMALE; HEADACHE; HUMAN; HYPERGLYCEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOOTH DISEASE; XEROSTOMIA;

EID: 0034620538     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.54.3.588     Document Type: Article

References (33)

1. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer's disease. Can J Neurol Sci 1989; 16:516-527.
2. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994; 151:1105-1113.
3. Aisen PS, Pasinetti GM. Glucocorticoids in Alzheimer's disease: the story so far. Drugs Aging 1998;12:1-6.
4. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996;47:425-432.
5. Curran M, Middleton D, Edwardson J, et al. HLA-DR antigens associated with major genetic risk for late-onset Alzheimer's disease. Neuroreport 1997;8:1467-1469.
6. Aisen PS, Luddy A, Durner M, Reinhard JF Jr, Pasinetti GM. HLA-DR4 influences glial activity in Alzheimer's disease hippocampus. J Neurol Sci 1998;161:66-69.
7. McEwen BS. Re-examination of the glucocorticoid hypothesis of stress and aging. Prog Brain Res 1992;33:365-383.
8. Lupien S, De Leon MJ, De Santi S, et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci 1998;1:69-73.
9. Leverenz JB, Wilkinson CW, Wamble M, et al. Effect of chronic high-dose exogenous cortisol on hippocampal neuronal number in aged nonhuman primates. J Neurosci 1999;19: 2356-2361.
10. Aisen PS, Marin D, Altstiel L, et al. A pilot study of prednisone in Alzheimer's disease. Dementia 1996;7:201-206.
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group. Neurology 1984;34: 939-944.
12. Folstein M, Folstein S, Mchugh P. The Mini-Mental State Examination. J Psychiatr Res 1975;12:189-198.
13. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
14. Thal LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 1996;47:705-711.
15. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
16. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114:797-811.
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
18. Overall JE, Gorham DR. Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
19. Overall JE, Beller SA. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit. J Gerontol 1984;39:187-193.
20. Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994;21:1283-1286.
21. Osaka H, Mukherjee P, Aisen PS, Pasinetti GM. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem 1999;73:303-311.
22. Mattson MP, Barger SW, Furukawa K, et al. Cellular signaling roles of TGFBeta, TNFAlpha and BetaAPP in brain injury responses and Alzheimer's disease. Brain Res Rev 1997;23: 47-61.
23. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43: 1609-1611.
24. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999;53:197-201.
25. Breitner JC, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994;44:227-232.
26. The Canadian Study of Health, Aging. Risk factors for Alzheimer's disease in Canada [see comments]. Neurology 1994;44: 2073-2080.
27. Breitner JCS, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995;16:523-530.
28. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler NMB, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam study. Neurology 1995;45:1441-1445.
29. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48: 626-632.
30. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-55.
31. Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998;87:319-324.
32. Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GM. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J Neurosci Res 1999;57:295-303.
33. Kaufmann WE, Andreasson KL, Isakson PC, Worley PF. Cyclooxygenases and the central nervous system. Prostaglandins 1997;54:601-624.